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Copyright © 200? JCBN 200? This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. In this study we investigated if peroxisome proliferator activated
receptor β/δ activation protects from copper induced acute liver
damage. Mice treated with copper had significant body weight
loss, serum alanine aminotransferase increase, modest changes in
liver histology, increase of tumor necrosis factor α and macrophage
inflammatory protein 2 mRNA and 8 hydroxy 2' deoxyguanosine.
Mice treated with copper and peroxisome proliferator activated
receptor β/δ agonist GW0742 had significantly less body weight
loss, less serum alanine aminotransferase increase, less tumor
necrosis factor α, macrophage inflammatory protein 2 and 8 
hydroxy 2' deoxyguanosine upregulation than copper treated mice.
The opposite effect was observed in mice treated with copper and
peroxisome proliferator activated receptor β/δ antagonist GSK0660.
In vitro, copper induced reactive oxygen species, which was lower
in cells treated with GW0742 or transfected with peroxisome
proliferator activated receptor β/δ expression vector; together,
transfection and GW0742 had an additive reactive oxygen species 
reducing effect. Copper also upregulated Fas ligand and Caspase
3/7 activity, effects that were significantly lower in cells also
treated with GW0742. In conclusion, peroxisome proliferator 
activated receptor β/δ activation reduced copper induced reactive
oxygen species, pro inflammatory and acute phase reaction cyto 
kines in mice liver. Peroxisome proliferator activated receptor β/δ
agonists could become useful in the management of copper 
induced liver damage.
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Introduction Copper toxicity is a rare but important cause of liver failure.
Copper toxicity occurs only on acute accidental poisoning
with copper sulfate or upon an insidious onset as in idiopathic
copper toxicity, which is an even more rare condition whose
pathogenesis is not quite well understood yet; or in Wilson’s
disease (WND)(1,2) which is the model disease for copper toxicity.
WND is an autosomal recessive disorder in which copper trans-
port from the hepatocytes to bile flow and incorporation of copper
into ceruloplasmin are impaired.(3) This situation leads to excess
copper accumulation in several organs, particularly liver and
brain; however, liver damage is the common condition in copper
toxicity. It has been proposed that the mechanism of copper
toxicity is via generation of free radicals which are strongly linked
to inflammation, fibrosis and apoptosis that eventually leads to
liver failure.(4) One of WND’s form of clinical presentation is
fulminant WND; condition for which plasmapheresis and chela-
tion therapy have no demonstrated benefit in mortality, but remain
the only bridge to transplantation in these patients.(5)
Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) is
the last member of the PPAR’s family to be carefully studied. It
is ubiquitously expressed in most tissues, with higher expression
in liver, intestine and keratinocytes.(6,7) Its activation improves
glucose homeostasis, increases serum HDL cholesterol, increases
fatty acid catabolism in muscle, mediates terminal differentiation
and inhibits cell proliferation in different models.(8–10) PPARβ/δ
also has anti-inflammatory effects including inhibition of cytokine
production, modulation of cell adhesion molecules and inhibition
of nuclear factor κB (NFκB) signaling. Besides the mentioned
characteristics and many other metabolic functions, PPARβ/δ has
been described to ameliorate carbon tetrachloride induced liver
toxicity.(9,11)
Recent reports suggest that PPARβ/δ has an important role in
oxidative stress; for example, PPARβ/δ activation protects cardio-
myoblasts(12) and umbilical vein endothelial cells from oxidative
stress-induced apoptosis(13) and promotes reversal of metabolic
abnormalities, reduces oxidative stress and increases fatty acid
oxidation in obese men.(14) PPARβ/δ null mice have larger histo-
logical damage and higher levels of damage markers [Alanine
aminotransferase (ALT)] than wild type mice when treated with
known hepatotoxicants.(9,11) Since PPARβ/δ appears to have a
protective role in oxidative stress-induced injury and prevents
carbon tetrachloride (CCl4)-induced liver damage, we investigated
if PPARβ/δ protects from copper-induced liver damage through
reduction of oxidative stress, inflammation and apoptosis.
Materials and Methods
Reagents. The following reagents were purchased from
Sigma Aldrich Co. (St. Louis, MO) unless otherwise stated. The
highly specific PPARβ/δ agonist GW0742 and the antagonist
GSK0660 were diluted first in dimethylsulfoxide (DMSO) and later
in culture media for in vitro studies (DMSO less than 1:100 000)
and in NaCl 0.9% for in vivo studies (DMSO less than 1%).
Copper sulfate and Nitriloacetate (NTA) were diluted in saline
solution into 0.08 mol/L and 0.16 mol/L respectively and mixed
at a molar ratio of 1:4 (modified from Toyokuni et al.)(15) for in
vivo studies. Copper sulfate was diluted in distilled water and
then in culture media for in vitro experiments. Fresh dilutions of
all reagents were prepared prior to each experiment.
In vivo study. Animal experiments were approved by the
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Ethics Committee for Animal Experimentation of Shimane Uni-
versity and its rules were followed, assuring human care to all the
animals used. Six weeks old BALB/c mice were purchased form
CLEA Japan Inc. and divided into groups of 5 under day:night
cycles of 12:12 h, fed NMF chow and water ad libitum. At least
one week after their arrival to the animal experimentation facilities,
mice were treated for 3 days in a row and sacrificed on day 4.
Group #1 served as control, receiving the corresponding oral and
intraperitoneal vehicles of the substances given to the other
groups. Group #2 was treated with 10 mg/kg/day of the PPARβ/δ
agonist GW0742 by oral gavage. Group #3 was treated with 1 mg/
kg/day I.P. of PPARβ/δ antagonist GSK0660. Group #4 was
treated with 10 mg/kg/day I.P. of copper in form of copper-
nitriloacetate (NTA). Group #5 was treated with 10 mg/kg/day of
copper I.P. and with 10 mg/kg/day of GW0742 P.O. Group #6
was treated with 10 mg/kg/day of copper I.P. and 1 mg/kg/day of
GSK0660 I.P.
Mice body weight was assessed before treatment on day 1 and
on day 4 before being sacrificed by inhalation of diethyl ether.
Blood sample was taken by cardiac puncture to later assess the
concentration of serum ALT. Mice were dissected and the liver
was removed, part of the liver was snap frozen in liquid nitrogen
and kept at −80°C for protein assays, other part was placed in
abundant volume of RNAlater (Ambion, Inc.) and other part was
preserved for histology.
Histology. Liver tissue was fixed in 10% formalin and
embedded in paraffin. Sections were mounted and stained with
hematoxylin and eosin and examined under light microscopy. As
histological changes induced by copper and other reagents were
expected to occur diffusely in the liver, we examined the largest
section of each sample and representative changes observed in the
sections were selected and included in Fig. 1.
RNA analysis. Total RNA was isolated from liver tissue
using the RNeasy mini Kit (QIAGEN) and from cultured cells
using Isogen (Nippon Gene Co., Toyama, Japan) as described in
their protocols. RNA quantity and quality were assessed by spectro-
photometry with NanoDrop® ND-1000; upon doing this, 1 μg of
total RNA was reverse-transcriptased with the StrataScript® First
Strand Synthesis System (Stratagene, La Jolla, CA) according to
the manufacturer’s instructions. RT-PCR was performed by
SYBR® Green (Applied Biosystems, Foster City, CA) method
with STEPONEPLUSTM system (Applied Biosystems, Foster City,
Fig. 1. Liver histology. Mice were treated for 3 days with 10 mg/kg/day of copper and 10 mg/kg/day of PPARβ/δ agonist (GW0742) and/or 1m g / k g /
day of the PPARβ/δ antagonist (GSK0660) and sacrificed at day #4. (A) Control mice were treated with the corresponding vehicles. (B) Modest vacuoliza 
tion in cells around the central vein and atrophic degeneration was observed in the liver of mice treated with copper. No obvious changes were
observed in mice that received GW0742 (C) or copper+GW0742 (D). Mice treated with GSK0660 alone show some vacuolization of cells and changes
in nucleus: cytoplasm ratio (E). The mentioned changes were more noticeable in the mice that received copper and GSK0660 (F). Liver of all mice in
each group were processed, assessing all fields in one section of each; a representative field of each group was selected for this figure. Hematoxylin
and eosin staining.doi: 10.3164/jcbn.10 139
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CA). The expression of tumor necrosis factor α (TNFα), macro-
phage inflammatory protein 2 (MIP-2) and the house keeping gene
GAPDH in mice (Mus musculus) tissue were evaluated using the
following primers: TNFα, forward primer, 5'-GAC AAG GCT
GCC CCG ACT A-3'; reverse primer, 5'-CGG CAG AGA GGA
GGT TGA CT-3'; MIP-2, forward primer, 5'-GGC CCA AGA
TCC GCT ACA-3'; reverse primer, 5'-GTG TGG GTA CTT TGG
CTT CAT TT-3; GAPDH, forward primer 5'-CAT GGC CCT TCC
GTG TTC CTA-3', reverse primer RV: 5'-GCG GCA CGT CAG
ATC CA-3'. The expression of Fas ligand (FasL) and GAPDH
genes in HepG2 cells (Homo sapiens) were assessed with the
following primers: FasL, forward primer: 5'-AGG AAA GTG
GCC CAT TTA ACA G-3', reverse primer: 5'-CCA GAA AGC
AGG ACA ATT CCA TAG-3'; human GAPDH, forward primer
5'-CCA CAT CGC TCA GAC ACC-3', reverse primer RV: 5'-
TGA CCA GGC GCC CAA TA-3'.
In vitro study. The human hepatoma cell line HepG2 was
obtained from ATCC (Manassas, VA), cultured and maintained in
DMEM media (GIBCO Products, Carlsbad, CA) supplemented
with Fetal Bovine Serum (ATCC Inc., Manassas, VA) to 10% of
the final volume and penicillin-streptomycin (GIBCO Products,
Carlsbad, CA) to a 1:100 dilution. Experiments were carried out
with complete growth media unless otherwise stated. Maintenance
and experimental cell cultures were kept at 37°C and 5% CO2.
Cell proliferation assays. The CellTiter96®AQUEOUS Non-
Radioactive Cell Proliferation Assay (Promega Corp. Madison,
WI) method was used to assess cells in proliferation and chemo
sensitivity. The protocol was followed and adapted to the needs of
this study. HepG2 cells were seeded in 96 well plates and treated
with different concentrations of CuSO4 and GW0742 for 24 to
48 h; the formation of formazan was measured with an ELISA
plate reader (BioRad, Hercules, CA) at 490 nm 4 h after adding
the PMS/MTS solution.
Intracellular reactive oxygen species (ROS) determina 
tion. Intracellular ROS were determined by fluorometry using
the oxidation-sensitive probe 5-(and-6)-carboxy-2',7'-dichlorodi-
hydrofluorescein diacetate (carboxy-H2DCFDA) (Molecular
Probes, Inc. Eugene, OR) according to the manufacturer’s instruc-
tions. Briefly, HepG2 cells were seeded in 96 well plates and
transfected with PPARβ/δ expression vector or empty vector; 6 h
later media was changed to conditioned media (containing copper
sulfate and/or GW0742). Twenty four hours after adding condi-
tioned media cells were loaded carboxy-H2DCFDA probe and
fluorescence was read 4 h later.
Caspase 3/7 activity determination. Caspase 3/7 activity
was measured using Apo-ONE® Homogeneous Caspase-3/7
Assay (Promega Corp. Madison, WI) according to instructions.
Briefly, HepG2 cells were seeded in white 96-well plates and
treated with different concentrations of copper and GW0742.
After 18 h of treatment, Apo-ONE® Caspase-3/7 reagent was
added to each well and fluorescence was read 6 h later (Fluo-
roskan Ascent FL). Each experiment was performed in triplicate.
Plasmids and transient transfection assays. Full-length
human PPARβ/δ cDNA (Genbank accession number NM_006238)
was amplified by PCR and cloned into an eukaryotic TA cloning
pCR3.1 expression vector (Invitrogen Corporation, Carlsbad,
CA). HepG2 cells were seeded in 6 or 24-well plates and
transfected when cultures reached 50–70% confluency using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol. Eighteen to twenty four hours later,
transfected cells were treated with conditioned media as required.
Western blot. Protein was extracted from cultured cells
using RIPA buffer plus HALT Protease and phosphatase inhibitor
cocktail (Thermo Scientific, Rockford, IL) according to the
manufacturer’s protocol. Sixty micrograms of protein per lane
were loaded and fractionated by 10% SDS-PAGE gel (TEFCO,
Tokyo, Japan). After fractionation, proteins were transferred to a
polyvinylidene difluoride membrane (Amersham Biosciences
Inc., UK) and later blocked with 5% milk/TTBS. Incubation with
specific first antibodies was done overnight at 4°C and secondary
antibodies for 2 h at room temperature. PPARδ protein was
detected with PPARδ polyclonal antibody (Cayman Chemical,
Ann Arbor, MI) and the β-actin protein was detected with
monoclonal anti-β-actin clone AC-15 (Sigma, St. Louis, MO) and
reacted with Polyclonal Rabbit anti-mouse immunoglobulins/HRP
(Dako, Denmark) respectively.
8 hydroxy 2' deoxy Guanosine (8 OHdG) EIA. First, DNA
purification from mouse liver tissue was performed with
QIAamp® DNA Mini kit (QIAGEN, Alameda, CA) according to
manufacturer’s protocol. After purification, DNA was denatured
by boiling for 10 min and digested with nuclease P1 (Sigma,
Japan) at 37°C for 30 min. pH was adjusted to 8.0, alkaline phos-
phatase was added and inactivated by boiling after 30 min of
incubation at 37°C. Samples were immediately kept in ice for at
least 10 min before performing 8-OHdG enzyme immunoassay.
8-OHdG ELISA kit was obtained from Cayman Chemical (Ann
Arbor, MI) and ran on samples after DNA purification and diges-
tion as mentioned above. ELISA assay was performed according
to manufacturer’s protocol. Data analysis was performed with
Cayman’s data analysis spread sheet (www.caymanchem.com/
analysis/eia) and later each sample was normalized to the concen-
tration of DNA.
Statistical analysis. Data are presented as mean ± SEM.
Student’s  t test was used to examine the differences between
experimental groups of the in vitro studies and the non-parametric
Mann-Whitney-Wilcoxon U test was used to examine the differ-
ences between experimental groups of the in vivo studies. A value
of p<0.05 was considered significant.
Results
PPARβ/δ agonism protects from copper induced liver
damage. To test the hypothesis that PPARβ/δ activation
protects from copper-induced liver damage, BALB/c mice were
treated for 3 days with intraperitoneal injections of copper and
the highly specific PPARβ/δ agonist GW0742 or the PPARβ/δ
antagonist GSK0660. Normal histology is observed in the liver
of control mice that received the corresponding vehicles P.O. and
I.P. (Fig. 1A). As well, mice treated with GW0742 alone (Fig. 1C)
did not show obvious histological changes. Mice treated with
GSK0660 alone (Fig. 1E) show some vacuolization of cells and
changes in nucleus:cytoplasm ratio. In mice treated with copper
nitriloacetate it was possible to observe modest vacuolization in
cells around the central vein and atrophic degeneration in the liver
(Fig. 1B). The latter histological changes were not observed in
the mice that received copper and PPARβ/δ agonist GW0742
(Fig. 1D), but were more severe in mice treated with copper and
the PPARβ/δ antagonist GSK0660 (Fig. 1F).
Average serum ALT in the control group was 59.5 IU/L,
average that increased to 161.6 IU/L (p<0.05) in the group treated
with copper. Mice treated with copper and GW0742 had an
average ALT of 46.5 IU/L, which is not significantly different
from the serum ALT of the control group but significantly lower
than ALT of mice treated with copper alone (p<0.05). Mice treated
with copper and PPARβ/δ antagonist GSK0660 had a serum ALT
of 108.5 IU/L which is comparable to those treated with copper
and significantly higher than that in mice that received only
GSK0660 (46.0 IU/L) or control (p<0.05) (Fig. 2A).
Mice body weight was assessed as a measure of mice general
condition and by the end of the experiment, important changes in
body weight were observed in the different groups. Control group
did not gain weight during the 4 experimental days probably due
to the administration of DMSO (GW0742’s vehicle) by oral
gavage. Mice treated with GW0742 alone had a small but
significant weight loss of 3% (p<0.05). The group of mice treated
with copper alone lost a significant 18% of body weight (p<0.01), J. Clin. Biochem. Nutr. | July 2011 | vol. 49 | no. 1 | 45
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decrease that was less severe (13%) in the group treated with
copper and GW0742 (p<0.05). The group treated with copper and
GSK0660 lost 20% of body weight (p<0.05) (Fig. 2 B and C).
mRNA expression of the acute phase reaction stimulant TNFα
in the liver of these mice was evaluated. TNFα mRNA signifi-
cantly increased to 2.72 fold in mice treated with copper (p<0.05).
TNFα mRNA expression was 1.85 fold in the mice treated with
copper and PPARβ/δ agonist GW0742, which is significantly
lower than in those treated with copper alone (p<0.05). The mice
that received PPARβ/δ antagonist GSK0660 alone had a 3.54 fold
expression of TNFα mRNA compared with the control, expres-
sion that rose to 7.64 fold in mice that received copper and
GSK0660 (p<0.05) (Fig. 3A).
The mRNA expression of the inflammatory cytokine MIP-2
was also evaluated in the liver of the different groups. The liver of
mice treated with copper alone had a 10.71 fold upregulation of
MIP-2 mRNA (p<0.05). The upregulation of MIP-2 induced by
copper was reduced by half in mice that also received the PPARβ/
δ agonist (5.99 fold, p<0.05). Mice treated with copper and
PPARβ/δ antagonist had an upregulation of MIP-2 of 5 fold com-
pared with mice treated with copper alone, this corresponds to
54.51 fold when compared with control mice (p<0.05) (Fig. 3B).
8-OHdG is a product of oxidative stress damage to DNA; we
assessed its presence in liver DNA of mice treated with copper,
GW0742 and GSK0660. Liver of mice treated with GW0742
alone had almost same amount of 8-OHdG as control group, 8.10
and 8.95 picogram per microgram (pg/μg) of DNA respectively.
The liver of mice treated with GSK0660 had over 3 times the
concentration of control group, 28.68 pg/μg of DNA (p<0.005)
while liver of mice treated with copper alone had almost double
concentration of 8-OHdG than control mice, 17.25 pg/μg of
DNA (p<0.05). Administration of GW0742 to mice challenged
with copper reduced the increase of 8-OHdG by half, to 12.90 pg/
μg of DNA (p<0.05). The combination of copper and GSK0660
induced 8-OHdG to 22.83 pg/μg of DNA which is comparable to
the concentration observed in mice treated with copper and with
GSK0660 alone (p<0.05 vs control) (Fig. 3C).
PPARβ/δ reduces ROS. HepG2 cells were treated with
copper sulfate and GW0742 to evaluate ROS production. First
we determined that copper, at concentrations of 16, 32 and 64 μM,
induces ROS formation in a dose-dependent manner (Fig. 4A).
ROS induced by 64 μM of copper sulfate in HepG2 cells was
significant and dose dependently lower in cells also treated with
0.1 and 1 μM of GW0742 (p<0.05 and <0.01 vs copper, respec-
tively) (Fig. 4B).
To further evaluate the role of PPARβ/δ in the reduction of
ROS, we transfected HepG2 cells with PPARβ/δ full length
expression vector. In Fig. 4C it is possible to observe the expres-
sion of PPARβ/δ at mRNA and protein levels in control and in
transfected HepG2 cells. Cells overexpressing PPARβ/δ had
significantly less ROS formation than mock transfected cells
(p<0.05). Furthermore, cells over expressing PPARβ/δ and treated
with GW0742 had an enhanced reduction of ROS when compared
with those only transfected with PPARβ/δ expression vector
(p<0.05) and those mock transfected (p<0.01) (Fig. 4D).
PPARβ/δ reduces copper induced apoptosis. The effect of
GW0742 and copper sulfate on HepG2 cells was assessed using
the MTS assay for chemosensitivity and cytotoxicity. First, we
determined that 24 h of GW0742 at concentrations ranging from
0.1 μM to 10 μM did not induce changes in HepG2 viability (data
not shown). Next, cells were treated with 64 μM of copper and
0.1–1 μM GW0742 for 24 h. Copper alone reduced cell viability
by 20% (p<0.00005), reduction that was significantly and dose-
dependently lower in cells co-treated with 0.1 and 1 μM of
GW0742 (p<0.005, p<0.0001, respectively) (Fig. 5A). To further
analyze the effect of copper and PPARβ/δ agonism on cell viability,
the apoptosis inducer FasL mRNA was assessed by QPCR. Under
the same conditions mentioned above, copper alone upregulated
Fig. 2. Serum ALT and mice body weight. (A) Control mice had an
average ALT concentration of 59.5 UI/L, concentration that significantly
increased to 161 UI/L in mice treated with copper. Serum ALT in mice
treated with copper and GSK0660 was 108 UI/L, which is not significantly
different to the increase observed in mice treated with copper alone.
ALT in mice treated with copper and GW0742 was 46.5 UI/L, what is
significantly lower than in mice treated with copper alone and
comparable to control group (*p<0.05 vs control; †p<0.05 vs copper).
(B, C) Body weight was assessed before treatment on day 1 and before
sacrifice on day 4. Average body weight and relative changes in body
weight between day 1 (100%) and day 4 can be observed in B and C
respectively. Copper alone induced a significant 18% decrease in body
weight, decrease that was still significant but less important in those
that also received GW0742 (13%). Mice treated with copper and
GSK0660 lost a significant 20% of body weight. GW0742 induced a
small but significant 3% body weight loss. Error bars represent SEM and
p value was assessed by Mann Whitney Wilcoxon U Test (*p<0.05,
**p<0.01, ***p<0.001).doi: 10.3164/jcbn.10 139
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FasL expression in HepG2 cells by 2.5 fold (p<0.05); co-treatment
with 0.01, 0.1 and 1 μM GW0742 reduced FasL upregulation to
2.1, 1.5 (p<0.05) and 0.91 (p<0.05) fold respectively (Fig. 5B).
Downstream in the apoptosis pathway, caspase 3/7 activity was
significantly upregulated by 16, 34 and 64 μM copper. Copper-
induced caspase 3/7 activity was significantly reduced in cells also
treated with 0.1 μM of GW0742 (p<0.05). This reduction was
observed even in cells that were not challenged with copper
(Fig. 5C).
Discussion
In this study, PPARβ/δ ligand activation protected BALB/c
mice from liver damage induced by copper while the use of a
novel PPARβ/δ antagonist aggravated the outcome of mice
challenged with copper. Liver damage and failure induced by
copper is rare and presents mainly as WND, which is a slow
progressive accumulation of copper that affects the liver, brain,
kidneys and in rare cases presents as acute liver failure with
hemolysis.(5,16) Even though WND is a condition that, if treated
appropriately, confers the patient a quite normal life style and
survival there is no therapy with proven benefit to treat patients
that present with acute liver failure and hemolysis. However, in
isolated cases, plasmapheresis plus copper chelants have success-
fully been used as a bridge to transplantation.(5) Some reports
describe survival of independent cases where antioxidants like
vitamin A and E have been used as ROS scavengers against
copper and CCl4, but these are usually case reports that lack of
further research or long term effects.(17,18)
A study in rats by Toyokuni et al.(15) caught our attention as
9 mg/kg/day in the form of copper nitriloacetate induced hepato-
megaly, hemoglobinuria and jaundice in Wistar rats within 12 h
and death within 72 h. This condition of hipercupremia and its
consequent liver damage, hemolysis and death within a short time
could be used to simulate an important part of the physiopathology
of fulminant WND. Furthermore, copper distribution and histo-
logical changes achieved  with long term administration of copper
nitriloacetate were comparable to those observed in WND.(15) We
reproduced their findings as mice died within 96 h from the initia-
tion of copper therapy and significant weight loss was observed
in the first 4 days. The short duration of our study and the lack of
chronic copper storage and inflammation resulted in a non-florid
histology; as well, it must be considered that hemolysis played a
key role in death of rats in the previously mentioned study, condi-
tion that is likely to be reproduced in our study. However, the type
and severity of changes in the group that received copper alone
and copper plus GSK0660 resemble those seen in WND patients(19)
and help us understand the protective role of PPARβ/δ activation
in copper-challenged mice.
The PPARβ/δ antagonist GSK0660 was recently described(20)
and reports using this antagonist have just started to emerge;
therefore, reports of in vivo use are very few and no description of
its specificity at this level has been reported. GSK0660 is known
for lacking bioavailability, therefore, first we had to develop a
pilot study to determine an adequate dosage of GSK0660 for our
main study. Doses as high as 10 mg/kg/day were safe for mice if
used alone, but doses higher than the ones used in this study plus
Fig. 3. TNFα and MIP 2 mRNA and 8 OHdG in liver of mice treated with copper and PPARβ/δ agonist (GW0742) or antagonist (GSK0660). (A) TNFα
was upregulated in all experimental groups; in mice treated with copper it increased to 2.72 fold and to 1.85 fold in the group treated with copper
and GW0742, significantly lower than copper alone group. The group treated with copper and GSK0660 experienced a steep upregulation of TNFα,
7.64 fold, significantly higher than in the group treated with copper only. (*p<0.05 vs control; †p<0.05 vs copper) (B) MIP 2 expression increased to
10.71 fold in mice treated with copper, increase that was reduced to 5.99 fold in mice treated with copper and GW0742 and steeply increased to
54.51 fold in those treated with copper and GSK0660. (*p<0.05 vs control; †p<0.05 vs copper) (C) 8 OHdG was assessed in liver DNA; mice treated
with copper had almost double 8 OHdG than control (8.95 vs 17.25 pg/μg of DNA). Copper induced increase of 8 OHdG was reduced by half in mice
also treated with GW0742. GSK0660 alone and in combination with copper significantly increased 8 OHdG 3 and 2 fold respectively. Error bars
represent SEM and p value was assessed by Mann Whitney Wilcoxon U Test (*p<0.05, **p<0.005 vs control; †p<0.05 vs copper). J. Clin. Biochem. Nutr. | July 2011 | vol. 49 | no. 1 | 47
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copper resulted in severe illness and death of the mice well before
the end point.
Mice treated with the PPARβ/δ antagonist alone showed a
significant upregulation of 8-OHdG and TNFα in liver, what
translates as an increase in liver injury probably due to the reduced
protection against ROS. It is important to recall that TNFα and
oxidative stress can induce each other,(21) what could result in
vicious circle of injury (Fig. 6). Moreover, the steep increase of
TNFα and MIP-2 in mice challenged with copper and GSK0660
and the opposite effect observed in mice challenged with copper
and GW0742, show the protective role of PPARβ/δ.
Copper’s toxicity appears to be via ROS formation and the
oxidative stress explained by the Harber-Weiss reaction.(19,21,22)
Our results showing that HepG2 cells treated with concentrations
of copper comparable to those found in WND patients go through
important oxidative stress that eventually induces apoptosis, coin-
cides with reports from other researchers.(21,22) We found that
PPARβ/δ activation reduced copper-induced ROS and apoptosis
in the same way it does in cardiomyoblasts exposed to hydrogen
peroxide(12) or in the liver of mice with iron overload.(23) Therefore,
we believe that PPARβ/δ activation reduces copper-induced FasL
and caspase 3/7 activity to induce a recovery in cell viability in
vitro. Transfection of PPARβ/δ expression vector by itself reduced
ROS formation, an effect that was additive when transfected
hepatoma cells were treated with GW0742. This indicates that
PPARβ/δ has a role in reduction of ROS and apoptosis.
PPARβ/δ is also known to inhibit reactive phase and pro-
inflammatory cytokines, apoptosis and have an important role in
liver metabolism.(9,24) These roles have been proven once again
under the particularity of copper-induced toxicosis (Fig. 6). In this
study we show that PPARβ/δ agonism reduces oxidative stress in
vitro and in vivo; moreover, reduction of oxidative stress-induced
DNA damage in liver tissue could be the reason of reduction of
apoptosis and recovery of cell viability in vitro. Since our findings
are comparable to that in which PPARβ/δ protected from CCl4
induced hepatotoxicity, PPARβ/δ agonists have the potential of
becoming an important tool in the management of some patients
with acute onset of WND and probably other causes of liver
damage and failure.(11,25) Furthermore, another PPARβ/δ agonist
named GW501516 is already being used in clinical trials with
favorable outcome;(14) however, more studies in humans are
necessary to assess the safety of PPARβ/δ agonism in the long
term. In the meanwhile, the evaluation of PPARβ/δ agonist in
animal models of WND, like ATP7B−/− mice or Long-Evans-
Fig. 4. Copper induced reactive oxygen species formation in HepG2 cells. (A) Copper at concentrations of 16, 32 and 64 μM induced ROS formation
in a dose dependent manner (*p<0.0005). (B) ROS induced by 64 μM of copper were significantly lower in HepG2 cells co treated with 0.1 and 1 μM
of GW0742 (*p<0.05, **p<0.01 vs copper). (C) Transfection of HepG2 cells with our PPARδ expression vector effectively increases PPARδ mRNA and
protein. (D) HepG2 cells transfected with PPARδ expression vector and exposed to 64 μM of copper had significantly less ROS than those transfected
with an empty vector and exposed to 64 μM of. Cells transfected with PPARδ expression vector and treated with 1 μM GW0742 had an additive
effect decreasing copper induced ROS formation copper (*p<0.05, **p<0.01 vs mock transfection; †p<0.05 vs PPARδ vector). Error bars represent
SEM and p value was assessed by Student’s t test.doi: 10.3164/jcbn.10 139
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Cinnamon rats, could give us a clearer idea of the effect of PPARβ/
δ agonism in WND-like settings. Studies with large numbers of
animals in order to have identifiable cases of fulminant hepatitis
and the waiting-time to reproduce chronic copper storage in tissue
represent an important challenge to the researchers.
In conclusion, the present study demonstrates that PPARβ/δ
activation protects mice from liver damage induced by copper
through reduction of TNFα, MIP-2 and oxidative stress-induced
DNA damage. The high expression of PPARβ/δ receptors in liver,
PPARβ/δ’s anti-inflammatory and anti-oxidative stress activity
and the fact that a PPARβ/δ agonist is already being used in
humans,(14) lead us to believe that the use of PPARβ/δ agonists
could become an important tool in the management of copper-
induced liver damage and probably other causes of liver damage
and failure where few therapeutic options are available. It is, of
course, mandatory to further study the safety of the agonist in
humans and its effect in specific models of liver damage and
failure.
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Abbreviations
MIP-2 macrophage inflammatory protein 2
8-OHdG 8-hydroxy-2'-deoxyguanosine
PPAR Peroxisome Proliferator Activated Receptor
ROS reactive oxygen species
TNFα tumor necrosis factor alpha
WND Wilson’s Disease
Fig. 5. Apoptosis in HepG2 cells treated with copper and PPARβ/δ agonist. (A) Copper at concentrations of 64 μM significantly reduced HepG2 cells
viability, reduction that was significantly lower in cells co treated with 0.1 and 1 μM of GW0742. (*p<0.00005 vs control; †p<0.005, ‡p<0.0001 vs
copper) (B) Fas ligand (FasL) mRNA expression significantly increased to 2.5 fold in cells treated with copper, expression that was reduced dose
dependently when cells were co treated with GW0742. (*p<0.05 vs control; †p<0.05 vs copper) (C) Caspase 3/7 activity also increased significantly in
cells treated with different concentrations of copper, activation that was significantly lower in cells co treated with 0.1 μM of GW0742. (*p<0.05 vs
control) Error bars represent SEM and p value was assessed by Student’s t test.
Fig. 6. In this study, we show that copper induces ROS, TNFα and MIP 2
in liver of BALB/c mice and ROS and FasL in HepG2 cells. These effects
were reverted by the administration of PPARβ/δ agonist and enhanced
by the administration of a PPARβ/δ antagonist. PPARβ/δ’s protective role
could be used in clinical settings of liver damage as agonists of this
receptor are already being tried in humans. J. Clin. Biochem. Nutr. | July 2011 | vol. 49 | no. 1 | 49
©2011 JCBN
A.A. Sanchez Siles et al.
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